Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Invested Capital (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Invested Capital for 5 consecutive years, with $567.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 29.46% year-over-year to $567.6 million, compared with a TTM value of $567.6 million through Dec 2025, up 29.46%, and an annual FY2025 reading of $567.6 million, up 29.46% over the prior year.
  • Invested Capital was $567.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $535.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $567.6 million in Q4 2025 and bottomed at $153.5 million in Q2 2022.
  • Average Invested Capital over 5 years is $372.5 million, with a median of $408.4 million recorded in 2023.
  • The sharpest move saw Invested Capital plummeted 38.59% in 2022, then soared 168.19% in 2023.
  • Year by year, Invested Capital stood at $185.0 million in 2021, then soared by 114.09% to $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then fell by 0.09% to $438.4 million in 2024, then rose by 29.46% to $567.6 million in 2025.
  • Business Quant data shows Invested Capital for KNSA at $567.6 million in Q4 2025, $535.4 million in Q3 2025, and $495.0 million in Q2 2025.